Towards Safer and More Effective CART Cell Therapy Through the Modulation of Myeloid Cytokines

通过调节骨髓细胞因子实现更安全、更有效的 CART 细胞疗法

• 批准号: 10538587
• 负责人: Saad J. Kenderian
• 金额: $ 61.94万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-12-09 至 2026-11-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10538587
• 关键词: Acute Lymphocytic Leukemia; Affect; Apoptosis; Apoptotic; B lymphoid malignancy; B-Cell Lymphomas; Blood specimen; CAR T cell therapy; CD19 gene; COVID-19; COVID-19 patient; Cell Death Induction; Cell Therapy; Cell physiology; Cells; Clinical; Clinical Trials; Collaborations; Data; Development; Etiology; Functional disorder; Funding; Goals; Granulocyte-Macrophage Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor Receptors; Hematopoietic; Impairment; In Vitro; Interleukin 6 Receptor; Interruption; Knock-out; Laboratories; Life; Mediating; Mediator; Multi-Institutional Clinical Trial; Multicenter Studies; Myelogenous; Myeloid Cells; Outcome; Outpatients; Pathway interactions; Patients; Phase; Phase I/II Clinical Trial; Pre-Clinical Model; Prevention; Publishing; Receptor Cell; Refractory; Relapse; Resistance; Resolution; Role; Sampling; Severities; Site; T-Lymphocyte; Testing; Therapeutic; Toxic effect; United States; Work; Xenograft Model; cancer therapy; cell behavior; chimeric antigen receptor; cohort; cytokine; cytokine release syndrome; first-in-human; improved; in vivo; insight; laboratory experiment; large cell Diffuse non-Hodgkin' s lymphoma; monocyte; monocyte colony stimulating factor; neurotoxicity; neutralizing antibody; novel; novel strategies; post-COVID-19; pre-clinical; prevent; receptor; response; severe COVID-19; tocilizumab; tool; transcription activator-like effector nucleases; tumor

PROJECT SUMMARY Despite the impressive activity of chimeric antigen receptor (CART) T cell therapy in the treatment of B-cell malignancies, the therapy is limited by the development of cytokine release syndrome (CRS) and neurotoxicity, as well as by lower rates of durable responses. While CRS is related to extreme elevation of cytokines associated with T cell expansion, the exact etiology of neurotoxicity is unknown and no options for treatment of neurotoxicity are available. It has, however, become apparent that inhibitory myeloid cells and cytokines contribute to both CART cell toxicities and resistance. We have identified granulocyte-macrophage colony- stimulating factor (GM-CSF) as a dominant driver for CART cell toxicity and inhibition of their functions. Our robust preclinical data indicate that GM-CSF inhibition reduces monocyte activation, enhances CART cell functions and prevents the development of both CRS and neurotoxicity in a novel xenograft model for CART cell-associated toxicities. Our additional studies suggest that GM-CSF disruption in CART cells ameliorates their apoptosis, independent of its effect on myeloid cells. These findings were corroborated when we utilized GM-CSF depletion as a therapeutic strategy in patients with cytokine storm and severe Coronavirus Disease 2019, COVID-19. Based on this work, a Phase 1/2 multi-center study of GM-CSF neutralization after CART19 cell therapy was launched. Our central hypothesis is that depletion of GM-CSF results in modulation of myeloid cell behavior, amelioration of CART cell activation, reduction of CART cell associated toxicities, and enhancement of their efficacy. We will leverage our laboratory tools, novel preclinical models, and samples from this clinical trial to test our hypothesis. In Aim 1 of this project, we will examine the interactions between GM-CSF and monocytes after CART cell therapy. In Aim 2 of this project, we will study the effect of GM-CSF directly on CART cells, and Aim 3 will test how these changes affect toxicity and efficacy of CART19 cell therapy in the novel Phase 1/2 clinical trial. Completion of these Aims will identify novel insights into the toxicity and activity of CART cells and will develop a new strategy to prevent CART cell associated neurotoxicity and CRS, potentially enabling the outpatient administration of CART cell therapy.

项目摘要 尽管嵌合抗原受体（CART）T细胞疗法在治疗B细胞白血病中具有令人印象深刻的活性， 对于恶性肿瘤，该疗法受到细胞因子释放综合征（CRS）和神经毒性的发展的限制， 以及较低的持久反应率。而CRS与细胞因子的极端升高有关 与T细胞扩增相关，神经毒性的确切病因尚不清楚， 有神经毒性。然而，很明显，抑制性骨髓细胞和细胞因子 导致CART细胞毒性和耐药性。我们发现了粒细胞巨噬细胞集落- 刺激因子（GM-CSF）作为CART细胞毒性和抑制其功能的主要驱动因素。我们 强有力的临床前数据表明，GM-CSF抑制减少单核细胞活化，增强CART细胞 在CART的新型异种移植模型中发挥作用并防止CRS和神经毒性的发展 细胞毒性我们的额外研究表明，CART细胞中的GM-CSF破坏改善了 它们的凋亡，独立于其对骨髓细胞的影响。这些发现得到了证实， GM-CSF耗竭作为细胞因子风暴和严重冠状病毒病患者的治疗策略 2019年，COVID-19。基于这项工作，CART 19后GM-CSF中和的1/2期多中心研究 细胞疗法已经启动。我们的中心假设是GM-CSF的缺失导致髓系细胞的调节， 细胞行为，改善CART细胞活化，降低CART细胞相关毒性，以及 提高其功效。我们将利用我们的实验室工具，新的临床前模型和样品， 来验证我们的假设在本项目的目标1中，我们将研究 CART细胞疗法后的GM-CSF和单核细胞。在本项目的目标2中，我们将研究GM-CSF的作用 Aim 3将测试这些变化如何影响CART 19细胞的毒性和功效。 新的1/2期临床试验中的治疗。完成这些目标将确定新的见解的毒性 并将开发一种新的策略来预防CART细胞相关的神经毒性， CRS，可能使门诊给予CART细胞疗法。